Compare TMDE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TMDE | BOLD |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 25.7M |
| IPO Year | N/A | 2024 |
| Metric | TMDE | BOLD |
|---|---|---|
| Price | $1.43 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 6.1M | 57.3K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.96 |
| 52 Week High | $4.77 | $1.78 |
| Indicator | TMDE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 52.62 |
| Support Level | $0.69 | $1.15 |
| Resistance Level | $2.75 | $1.19 |
| Average True Range (ATR) | 0.69 | 0.03 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 17.35 | 75.00 |
TMD Energy Ltd is engaged in marine fuel bunkering services specializing in the supply and marketing of marine gas oil and marine fuel oil (including high sulfur fuel oil, low sulfur fuel oil and very low sulfur fuel oil), to ships and vessels at sea. It is also involved in the provision of ship management services for in-house and external vessels, as well as vessel chartering. It is currently operating with a fleet of nearly 15 bunkering vessels ranging from 540 dwt to 7,820 dwt, of which nearly nine (9) are double bottom and double hull vessels with an average cargo-carrying capacity of approximately 4,200 dwt each.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.